Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Seres's pioneering microbiome drug fails mid-stage trial

Nature Biotechnology volume 34, pages 1004–1005 (2016)Cite this article

Subjects

“These are unexpected clinical results,” said CEO Roger Pomerantz in a press release. The infection recurrence rates in the SER-109-treated groups failed to match expectations, prompting the company to review the results and the microbiome data it collected from patients and compare them with the results from the investigator-sponsored phase 1b that had raised high hopes for the drug. The Cambridge, Massachusetts, company intends to consult with the US Food and Drug Administration and make any appropriate adjustments to its development plans. The company declined an interview for this story, “given that we are actively conducting a root cause investigation of the SER-109 phase 2 study,” it said in an email.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Boca Raton, Florida

    Mark Ratner

Authors
  1. Mark Ratner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ratner, M. Seres's pioneering microbiome drug fails mid-stage trial. Nat Biotechnol 34, 1004–1005 (2016). https://doi.org/10.1038/nbt1016-1004b

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1016-1004b

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing